Tapinarof Cream 1% Once Daily for the Treatment of Extensive Atopic Dermatitis in Adolescents and Children: 4-Week Maximal-Use Trial

Main Article Content

Amy Paller
Adelaide A. Hebert
John E Jett
Philip M. Brown
David S. Rubenstein
Stephen Piscitelli

Keywords

Tapinarof, Aryl Hydrocarbon Receptor Agonist, Atopic Dermatitis, Maximal Usage, Trial Design, Pharmacokinetics, Children, MUPK, Topical

References

1. Weidinger S and Novak N. Lancet. 2016;387:1109–1122.

2. Bieber T. N Engl J Med. 2008;358:1483–1494.

3. Carroll CL, et al. Pediatr Dermatol. 2005;22:192–199.

4. Lewis-Jones S. Int J Clin Pract.2006;60:984–992.

5. Dermavant Sciences. VTAMA (tapinarof) cream, 1%: US prescribing information. 2022. https://www.vtama.com/docs/DMVT_VTAMA_PI.pdf. Accessed July 2022.

6. Lebwohl M, et al. N Engl J Med. 2021;385:2219–2229.

7. Strober B, et al. J Am Acad Dermatol. 2022. https://doi.org/10.1016/j.jaad.2022.06.1171.

8. Bissonnette R, et al. J Am Acad Dermatol. 2021;84:1059–1067.

9. Dermavant DOF [DMVT-505 Th2 Polarization; Apr 2015].

10. Dermavant DOF [DMVT-505 AD Mouse Model; Oct 2016].

11. Smith SH, et al. J Invest Dermatol. 2017;137:2110–2119.

12. Kim BE, et al. Allergy Asthma Immunol Res. 2018;10:207–215.

13. Peppers J, et al. J Am Acad Dermatol. 2019;80:89–98.

14. Paller A, et al. J Am Acad Dermatol. 2021;84:632–638.

15. Bissonnette R, et al. Clin Pharmacol Drug Dev. 2018;7:524–531.

16. Jett JE, et al. Am J Clin Dermatol. 2022;23:83–91.

17. Hanifin JM and Rajka G. Acta Dermatovener (Stockholm) Suppl. 1980;92:44–47.

Article Sidebar

Poster PDF
Published
Mar 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.138

Article Details

How to Cite
Paller, A., Hebert, A. A., Jett, J. E., Brown, P. M., Rubenstein, D. S., & Piscitelli, S. (2023). Tapinarof Cream 1% Once Daily for the Treatment of Extensive Atopic Dermatitis in Adolescents and Children: 4-Week Maximal-Use Trial. SKIN The Journal of Cutaneous Medicine, 7(2), s138. https://doi.org/10.25251/skin.7.supp.138
Issue
Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 > >>